Navigation Links
New Study Shows Impressive Results with Abutment-Free Sophono System
Date:2/7/2013

Boulder, Colo. (PRWEB) February 07, 2013

Children with the abutment-free, implantable bone conduction hearing device from Sophono, Inc., experienced significant improvement in hearing – without skin complications – according to a new study.

Sophono, Inc., is a Colorado-based medical device manufacturer. The Sophono Alpha System™ is the only abutment-free, implantable, bone-anchored hearing system on the market, treating those with conductive hearing loss, mixed hearing loss and single-sided deafness. Fitted to the patient’s head with the use of small, implantable magnets, the Sophono Alpha System eliminates the problems associated with other bone conduction hearing systems. These include drilling a hole in the patient’s skull and installing a very noticeable screw that pokes out through the skin on the side of the head.

The article summarizing the study findings, with preliminary results on how Sophono’s closed-skin bone-anchored implant worked in children with ear atresia, appears in the February issue of Otology & Neurotology. The study, conducted in Hôpital d’Enfants Armand-Trousseau (Paris Childrens’ Hospital) in 2012, evaluated the results of children between 6 and 9 years old. All had high-grade ear atresia, defined as the absence an external ear canal and resulting in the child’s inability to hear in the affected ear. A review of patient benefit at six months of use with the Sophono system showed that the children experienced the following.

1.    Hearing levels improved from severe conductive loss to nearly normal hearing.

2.    A high level of overall satisfaction – among both children and their parents

3.    No pain or skin complications

4.    Statistical and clinical improvement in speech-in-noise, an indication of how well the children could understand speech in a noisy environment

Study authors were: Françoise Denoyelle, M.D., Ph.D.; Nicolas Leboulanger, M.D., Ph.D.; Cyrille Coudert; Olivia Mazzaschi, M.D.; Natalie Loundon, M.D.; Eric Vicaut; Natacha Tessier; and Eréa-Noël Garabedian, M.D.

“The results that the article presents confirm the hearing performance Sophono continually sees with those using the Sophono Alpha System – in terms of hearing ability, speech understanding and high levels of satisfaction,” says Jim Kasic, president and CEO of Sophono. “Children, in particular, benefit from Sophono’s abutment-free technology.”

Sophono, Inc. (http://www.sophono.com)
Sophono, Inc., is a medical device manufacturer specializing in implantable, bone conduction hearing devices. The company’s products are designed for individuals suffering from severe to profound hearing loss or impairment. The Sophono Alpha 2™ System is the only abutment-free, implantable, bone-anchored hearing system available today. Treating those with conductive hearing loss, mixed hearing loss, and single-ear deafness, the FDA-cleared Alpha 2 device eliminates the problematic abutment of devices by using magnets to affix external sound processors.

Sophono corporate headquarters and manufacturing operations reside in Boulder, Colo. The company maintains an office in Germany, works with more than 20 distributors, and is actively selling in more than 30 countries.

(end)

Read the full story at http://www.prweb.com/releases/2013/2/prweb10405031.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. EU Study Finds UK Health Product Benefit Metric Flawed
2. Notre Dame study explores the potential benefits and threats of nanotechnology research
3. CSL Behring enrolls first patient in global pediatric Phase III pivotal study of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) to treat hemophilia B
4. University of Colorado Cancer Center Study Finds That Body's Ibuprofen, SPARC, Reduces Inflammation and Thus Bladder Cancer Development and Metastasis
5. Wysebridge Launches Patent Bar Exam Study Review
6. RPCI-Led Study: FAK Inhibitor Proves Effective Against Brain Tumors in Preclinical Studies
7. Spartan Bioscience Announces 6,000-Patient Study of Personalized Medicine for Cardiac Stents
8. Major Diabetes Peer-Review Journal Publishes Postive Results Of Ultradian Diagnostics Human Pilot Study
9. American Journal of Infection Control Study Validates ATP Testing for Monitoring Sanitation in Hospitals; Charm Sciences Test Verified
10. Study identifies targeted molecular therapy for untreatable NF1 tumors
11. Study Finds Proof of Acupuncture Success
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... PROVIDENCE, R.I. , April 25, 2017 /PRNewswire/ ... EpiVax, Inc. ("EpiVax") has licensed its novel immune-modulating technology ... in autoimmune disease and allergy. Tregitopes, ... discovered in human immunoglobulin by EpiVax CEO ... Martin. Similar to intravenous immunoglobulin G, an autoimmune ...
(Date:4/24/2017)... , April 24, 2017  Dante Labs announced today ... only EUR 850 (ca. $900). While American individuals have been ... first time Europeans can access WGS below EUR 1,000. ... crucial to leveraging genetic information to make informed decisions about ... ...
(Date:4/21/2017)... Muncie, IN (PRWEB) , ... April 21, 2017 , ... ... year to 11 high school graduates from across the nation. The scholarships are created ... of AMA member dues. , Scholarship criteria are set by the AMA Scholarship Committee, ...
(Date:4/20/2017)... Lilly and Company (NYSE: LLY ) will ... of migraine at the American Academy of Neurology (AAN) ... in Boston . ... and patient outcomes data for galcanezumab in patients with ... migraine headache days among patients with episodic migraine. Lilly ...
Breaking Biology Technology:
(Date:4/5/2017)... SEATTLE , April 5, 2017  The Allen ... the Allen Cell Explorer: a one-of-a-kind portal and dynamic ... large-scale 3D imaging data, the first application of deep ... edited human stem cell lines and a growing suite ... the platform for these and future publicly available resources ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
Breaking Biology News(10 mins):